ClinicalTrials.gg
CompletedNCT06446960APEDOCUpdated Oct 19, 2026

The Role of Peripheral Afferents in Modulating Post-stroke Central Pain

A Phase 3 interventional study of Lidocaine 20mg/ml and Levobupivacaine Hydrochloride 1.25 MG/ML in Stroke, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Phase 3, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France — 3 open to participants now, 3 under way, none of them phase 3. Stroke · Institut National de la Santé Et de la Recherche Médicale, France.

Enrollment
6th of 10
33 · median 39
Started
2024
with 1 other
Phase 3
Only one
of the 13
Registered
11th of 13
by date

Among the 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 3, and was the 11th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France, or all of them as a file.
02

Study summary

Central post-stroke pain (CPP) is extremely difficult to relieve and responds very poorly to analgesics targeting neuropathic pain, probably because the mechanisms underlying this pain remain poorly understood.

Stroke pain is traditionally considered to be of central origin and related to changes in the spinal cord and/or brain nociceptive systems. However, a recent study in a small cohort of patients has suggested that the peripheral nervous system (PNS) may have a role in the initiation and persistence of APD.

The main objective of this prospective randomised controlled bicentric study (Raymond Poincaré and Ambroise Paré) in double blind and parallel groups against placebo (3 arms) will be to evaluate the efficacy of two peripheral nerve blocks performed 14 days apart on spontaneous neuropathic pain after stroke. The active treatments used for the blocks will be either lidocaine 20 mg/ml or levobupivacaine 1.25 mg/ml or placebo (saline)

Read the detailed description

The primary endpoint will be the change in neuropathic pain intensity (assessed on an 11-point pain intensity scale), expressed as a difference in pain intensity between the value obtained before each block and that obtained 45 minutes after, corresponding to the maximum expected effect. Secondary endpoints will include exertional pain, pain quality, % relief, clinical global impression, pain assessment on a patient diary for a fortnight after each block and adverse events.

Patients will be randomised to receive one of 3 study treatments (lidocaine 2%, levobupivacaine 1.25 mg/ml or placebo). The treatment protocol will involve 2 perineural blocks performed 14 days apart. Assessment will continue for up to 2 weeks after each block, i.e. up to one month after the start of treatment. An evaluation of pain will be carried out before the block and after each block, at 45 minutes and at 5 hours, and then daily by the patient on a self-evaluation booklet for the 14 days following each block.

Randomisation will be centralised on a server from a list drawn up in advance by computer rogramme, balanced by blocks of variable size. Allocation between the 3 arms will be done according to a balanced 1:1:1 distribution. Treatments will be numbered from 1 to n, and allocated to patients in the chronological order of their inclusion in the trial.

Patients will be randomised on the day of treatment using a centralised computerised randomisation procedure to receive one of the 3 study treatments (lidocaine 20 mg/ml levobupivacaine 1.25 mg/ml or saline). No matching by age or duration of pain is planned, as randomisation usually results in groups matched at baseline on these criteria. The treatment will be administered over two visits performed 14 days apart by a qualified anaesthetist using the peri-nervous route according to current ecommendations (see above). Only one randomisation will be performed at baseline, so that a patient on active treatment cannot receive placebo at a later date and vice versa (see figure 1).

The investigators plan to randomise 10 patients per group and a total of 30 patients to achieve 90% power with a two sided α risk=0.05,. Given the estimated premature discontinuation rate, the investigators consider it necessary to include 12 patients per group for a total of 36 patients.

This study opens the way to new therapeutic avenues for these patients who often fail all treatments

03

Conditions studied

  • Stroke

Keywords

  • Ischemic Stroke
  • Central Neuropathic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 years and over with no maximum age (blocks are generally very well tolerated in the very elderly)
  2. Pain in the upper or lower limb distal enough to be completely covered by a peripheral nerve block
  3. Chronic pain for at least 6 months
  4. Ischaemic or haemorrhagic stroke for at least 6 months documented clinically and by appropriate imaging (MRI)
  5. Post-stroke central neuropathic pain defined as pain occurring in the aftermath of stroke meeting the criteria for probable or defined neuropathic pain according to the NeuPSIG algorithm and with a DN4 screening questionnaire score of at least 4 out of 10.
  6. Spontaneous pain intensity greater than or equal to 4 out of 10 on an 11-point numerical scale (EN) at inclusion and randomisation (i.e. just before each block)
  7. Patients affiliated to a social security scheme or beneficiaries of such a scheme
  8. Stable oral analgesic pharmacological treatment for at least 2 weeks prior to inclusion
  9. Acceptance and signing of the

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness to sign an
  2. Person subject to a legal protection measure (safeguard of justice, curatorship, guardianship)
  3. Patients with ongoing psychiatric pathology (major depression, psychosis) or cognitive disorders that prevent a good understanding of the protocol and questionnaires
  4. Pain that is too widespread in one hemicycle or limb and cannot be adequately covered by blocks
  5. Ongoing drug or substance abuse
  6. Language (aphasia) or comprehension disorders, illiteracy
  7. Moderate to severe renal or hepatic impairment
  8. to local anaesthetics for use in perineural blocks (infection or acute inflammation in the injection area, known allergy).
  9. Pregnancy or breastfeeding
  10. Known to lidocaine, levobupivacaine, amide-linked local anaesthetics or to any of the contained in the specialities used in the study.
  11. Patients with recurrent porphyria or severe hypotension contraindicating treatment with lidocaine and/or levobupivacaine
  12. Current treatment with antiarrhythmic drugs causing torsades de pointes (amiodarone, disopyramide, quinidinics, sotalol...) or with antiarrhythmic drugs with local anaesthetic activity (mexiletine or class III antiarrhythmic drugs) and cannot be discontinued.
  13. Too little pain at the time of the blocks (\< 4 out of 10)
  14. Need to modify analgesic pharmacological treatment at the beginning or during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    lidocaine 20 mg/ml

    Name (INN and/or speciality) : Lidocaine 20 mg/ml Pharmaceutical form: Injectable Route of administration: Peri-Nervous Dosage for administration: 20ml Duration of treatment: 2 bolus administrations at 14 day intervals

    Drug: Lidocaine 20mg/ml

  • Experimental
    levobupivacaine 1.25 mg/ml

    Name (INN and/or speciality) : Levobupivacaine (Chirocaine), 1.25 mg/ml Pharmaceutical form: Injectable Route of administration: Peri-Nervous Dosage for administration: 20ml Duration of treatment: 2 bolus administrations at 14 day intervals

    Drug: Levobupivacaine Hydrochloride 1.25 MG/ML

  • Placebo comparator
    Sodium chloride (NaCl) 0.9

    Name (INN and/or speciality) : Sodium chloride (NaCl) 0.9 Pharmaceutical form: Injectable Route of administration: Peri-Nervous Dosage for administration: 20ml Duration of treatment: 2 bolus administrations at 14 day intervals

    Drug: Sodium Chloride 0.9% Inj

Interventions

  • DrugLidocaine 20mg/ml

    Drug page: LidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml

  • DrugLevobupivacaine Hydrochloride 1.25 MG/ML

    Drug page: LevobupivacaineStudies of LevobupivacaineLevobupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml

  • DrugSodium Chloride 0.9% Inj

    2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of two peripheral nerve blocks performed 14 days apart on spontaneous neuropathic pain after stroke. The active treatments used for the blocks will be either lidocaine 20mg/ml or levobupivacaine 1.25mg/ml or placebo (saline)

    The evolution in neuropathic pain intensity assessed on an 11-point pain intensity scale (0 = no pain: 10: maximum imaginable pain), expressed as a difference in pain intensity between the value obtained before each block and that obtained 45 minutes after, corresponding to the maximum expected effect. The values obtained before and after each block will first be analysed individually and then combined for the two successive blocks for each patient and the comparison will be between the three treatment arms, lidocaine 20mg/ml, levobupivacaine 1.25mg/ml or placebo Rationale for the choice of the main criterion : Pain intensity will be assessed on a numerical scale that corresponds to the usual validated measurement criterion and the choice of 45 minutes corresponds to the maximum effect of local anaesthetics

    Time frame: 24 months

Secondary outcomes

  1. - To evaluate the time course and duration of the effectiveness of the nerve blocks on spontaneous pain on a pain intensity scale completed daily by the patient on a self-evaluation booklet up to 14 days after each block.

    \- Comparison of the duration (in days) of efficacy of lidocaine 20 mg/ml levobupivacaine 1.25 mg/ml and placebo blocks on spontaneous and exertional pain assessed by an 11-point pain intensity scale (0 to 10) completed daily by the patient on a self-report diary, up to 14 days after each block.

    Time frame: 24 months

  2. - Evaluate the effectiveness of blocks on exercise pain

    \- Comparison of the efficacy of levobupicacaine 1.25 mg/ml, lidocaine 20 mg/ml and placebo on spontaneous and exertional pain assessed by an 11-point pain intensity scale (0 to 10) at 45 minutes and then at 5 hours after the block and then daily on a self-evaluation booklet, up to 14 days after each block

    Time frame: 24 months

  3. - Directly compare the efficacy of active blocks, i.e. lidocaine and levobupivacaine, on spontaneous and provoked pain (allodynia)

    * Comparison of the efficacy of lidocaine, levobupivacaine and placebo blocks on the intensity of rubbing pain if present (dynamic mechanical allodynia) assessed before treatment with a brush and then at 45 minutes and at 5 hours after each block. * Comparison of the efficacy of lidocaine, levobupivacaine and placebo blocks on spontaneous and provoked pain area (mechanical allodynia if present) assessed by a tracing (and then plotted on a graph allowing measurement of area in cm2) before treatment and then at 45 minutes and at 5 hours after each block using a method used in our previous studies

    Time frame: 24 months

  4. - Evaluate the effectiveness of each block on provoked pain (mechanical allodynia), mechanical, hot and cold pain thresholds and pain area

    \- Comparison of the efficacy of lidocaine, levobupivacaine and placebo blocks on mechanical pain and detection thresholds assessed by Semmes Weinstein monofilaments (calibrated from 0.057 g to 300 g) as well as on thermal pain and detection thresholds assessed by a thermotest before the treatment and at 45 minutes and at 5 hours after each block

    Time frame: 24 months

  5. - Evaluate the effectiveness of each block on the dimensions of neuropathic pain assessed by the NPSI questionnaire

    \- Comparison of the efficacy of lidocaine, levobupivacaine and placebo blocks on dimensions of neuropathic pain assessed by the NPSI questionnaire before treatment and at 45 minutes, and at 5 hours and 2 weeks after each block

    Time frame: 24 months

  6. - To evaluate the effectiveness of the blocks on the overall clinical impression, the percentage of relief as well as the satisfaction with the treatment

    Evaluation of adverse effects of lidocaine, levobupivacaine and placebo blocks after the blocks and up to 14 days after each block. * Efficacy of lidocaine, levobupivacaine and placebo blocks on patient (PGIC) and examiner (CGIC) clinical global impression at 45 minutes, and at 5 hours and 2 weeks after each block. * Proportion of responders to lidocaine, levobupivicaine and placebo treatments assessed at 45 minutes, ad at 5 hours and 2 weeks after each block.

    Time frame: 24 months

  7. - Assessing the adverse effects of each treatment

    \- Evaluation of adverse effects of lidocaine, levobupivacaine and placebo blocks after the blocks and up to 14 days after each block

    Time frame: 24 months

  8. - Assessing the maintenance of blinding by a blinding questionnaire at the end of the study

    \- Blinding assessment by a blinding questionnaire at the end of the study for each patient

    Time frame: 24 months

07

Study locations

2 sites
  • CHU Ambroise Paré
    Boulogne-Billancourt, 92100, France
  • Hôpital Raymond Poincaré
    Garches, 92380, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2026, 27 months.

Of 93 non-industry phase 3 interventional studies under Stroke, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 27 months is below that.

Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Sep 2026 → Jun 2026 and completion Sep 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Jun 6, 2024
StartActual
Feb 9, 2024
Primary completionActual
Jun 4, 2026was Sep 2026
CompletionActual
Jun 4, 2026was Sep 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Primary completion
Sep 8, 2026→Jun 4, 2026 (actual)
Oct 19, 2026
Study completion
Sep 8, 2026→Jun 4, 2026 (actual)
Oct 19, 2026
Enrollment
36 (estimated)→33 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    Primary completion Sep 8, 2026→Jun 4, 2026 (now actual)
    Study completion Sep 8, 2026→Jun 4, 2026 (now actual)
    Enrollment 36 (estimated)→33 (actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06446960
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Feb 9, 2024
Primary completion
Jun 4, 2026
Completion
Jun 4, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Levobupivacaine

Start the discussion